You are here
Theranica Raises $35M to Bring Innovative Migraine Device to the USA
NETANYA, Israel, March 18, 2019 /PRNewswire/ -- Theranica, a bio-medical technology company developing advanced electroceuticals for migraine and other prevalent diseases, announced the closing of its round B of financing, of $35 Million, led by aMoon, Israel's largest healthcare VC. All existing investors of the company – Lightspeed Venture Partners, LionBird, Corundum Open Innovation and Takoa – participated in the round.
Nerivio Migra®, the company's novel remote neuromodulation device for acute treatment of migraine, is currently under review of the FDA. In October 2018 the company completed a pivotal study with the device, the largest-ever clinical study conducted with a migraine device to support FDA clearance, spanning 12 clinical sites in the US and Israel, with almost 300 migraine patients. The study met its primary endpoint with high statistical significance, and demonstrated high efficacy, safety and tolerability.
"The new funds will allow the company to mass-produce the Nerivio Migra®, and – once cleared by the FDA – to deliver the device to millions of migraine patients in the USA," said Alon Ironi, CEO and co-founder of Theranica. "They will also enable further development, targeting additional clinical syndromes," added Ironi. "We chose to start with the USA because this is the largest single market for migraine and headache, and because we were highly impressed by the readiness of the American medical community to apply drug-free, non-addictive solutions for headache and other types of pain," Ironi explained.
"Theranica's vision and current stage align well with the investment strategy of our late stage fund," said Todd Sone, partner at aMoon. "Theranica's innovative migraine device combines excellent clinical efficacy, safety and tolerability, together with advanced digital technologies to maximize the benefit for patients."
"This new partnership with aMoon, together with the on-going support from our existing investors, gives Theranica the fuel to commercialize the product, bring it to the masses and ultimately improve migraine therapy worldwide, by turning this innovative, non-invasive, drug-free solution into the first line of treatment," said Dr. Shimon Eckhouse, Theranica's co-founder and chairman of the board.
The Nerivio Migra is Investigational Device, Currently Limited by US Federal Law to Investigational Use Only in the United States.
About Theranica: Theranica is a medical device company, founded in 2016 by Alon Ironi, Ronen Jashek, Rotislav (Slava) Barabash and Dr. Shimon Eckhouse, with the vision of combining advanced neuromodulation therapy with modern wireless technology to develop proprietary electroceuticals that address prevalent medical conditions and diseases.
About aMoon: aMoon is a global HealthTech Venture capital fund based in Israel, founded by Dr. Yair Schindel MD, former CMO of the Israeli Navy Seals and CEO of Israel's National Digital Bureau, and anchored by Marius Nacht, Co-Founder and Chairman of Check Point Software. The fund aims at accelerating cure for life-threatening diseases and reduce major cost-drivers in healthcare, by leveraging the growing convergence of healthcare and technology.
Ronen Jashek, VP marketing and Business development,
SOURCE Theranica Bio-Electronics